logo

Beigene (BGNE)



Trade BGNE now with
  Date
  Headline
12/15/2018 3:05:34 AM BeiGene Announces Updated Phase 1A/1B Data On Tislelizumab Presented At ESMO-IO Congress
12/10/2018 6:06:52 AM BeiGene To Present Data On Anti-PD-1 Antibody Tislelizumab
11/27/2018 6:34:36 AM Zymeworks And BeiGene Announce License Deal For Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 And ZW49
11/16/2018 7:05:32 AM BeiGene Announces Preliminary Clinical Data On PARP Inhibitor Pamiparib Presented At SNO
11/15/2018 7:11:48 AM BeiGene: NMPA Grants Priority Review Status To NDAs For Zanubrutinib And Tislelizumab In China
10/24/2018 7:11:57 AM BeiGene Announces Acceptance Of NDA In China And Top-Line Pivotal Data For Zanubrutinib
10/22/2018 7:20:34 AM BeiGene Presents Preliminary Clinical Data On PARP Inhibitor Pamiparib With Low-Dose Temozolomide At ESMO
10/12/2018 6:03:31 AM BeiGene Reports Updated Results From Phase 1 Clinical Trial Of Zanubrutinib
10/11/2018 6:02:53 AM MEI Pharma And BeiGene Announce Clinical Collaboration To Evaluate ME-401 In Combination With Zanubrutinib
9/20/2018 11:50:47 PM BeiGene Presents Results On Anti-PD-1 Antibody Tislelizumab In Chinese Patients With Lung Cancers
9/20/2018 4:49:25 AM BeiGene Presents Preliminary Results On Anti-PD-1 Antibody Tislelizumab
9/6/2018 6:02:33 AM BeiGene, SpringWorks Therapeutics Enter Into Global Clinical Collaboration To Evaluate Targeted Combination Therapy
8/31/2018 6:01:23 AM BeiGene Announces Acceptance Of NDA For Anti-PD-1 Antibody Tislelizumab In Hodgkin’s Lymphoma In China
8/9/2018 5:07:14 AM BeiGene Q2 Net Loss $156.89 Mln Or $2.92/ADS Vs Loss $60.55 Mln Or $1.52/ADS Last Year
8/9/2018 5:06:13 AM BeiGene Initiates New Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab Combined With Chemotherapy
7/24/2018 7:10:01 AM BeiGene Begins Global Phase 3 Trial Of PARP Inhibitor Pamiparib In Patients With Advanced Gastric Cancer
7/22/2018 4:32:02 PM BeiGene Plan To Pursue Accelerated Approval In US Of BTK Inhibitor Zanubrutinib In Waldenström Macroglobulinemia
7/22/2018 4:31:38 PM BeiGene Releases Results Of Pivotal Trial In China For Anti-PD-1 Antibody Tislelizumab In Hodgkin’s Lymphoma